THE PATIENTS’ CHARACTERISTICS AND NON-SURGICAL TREATMENT RESULTS FOR HYPOPHARYNGEAL CANCER IN SOUTHEAST OF IRAN: A 13-YEAR STUDY
Keywords:Hypopharyngeal neoplasm, Hypopharyngeal neoplasm, chemoradiotherapy, survival analysis.
AbstractBackground: Various modalities have been used to treat hypopharyngeal cancer. Non- surgical modalities include radiotherapy alone, sequential chemoradiation and concomitant chemoradiation or bio radiation. This study was conducted to evaluate the primary non-surgical treatment. Methods: A total number of 67 patients treated from March 2009 to January 2022 were enrolled in this study. The 2-year and 5-year survival rates were estimated using the Kaplan-Meier method. Log-rank test was used to compare the survival outcomes according to various factors. To define independent prognostic factors, we used Cox regression analysis. Results: The mean age of the patients was 56.2 years, and 55.2% of them were male. These patients were treated by radiation alone (9 patients) or induction chemotherapy followed by either radiation (4 patients), chemoradiation (33 patients), or bio-radiation (21 patients). The mean follow-up time was 18.12 months. The 2-year and 5-year overall survival rates were estimated to be 43% and 18%, respectively. Multivariate analysis showed that T stage, N stage, and treatment modality had a statically significant relationship with overall survival. Conclusion: The results of non-surgical treatment for hypopharyngeal cancer are not satisfactory. More studies are needed to investigate the role of salvage surgery.
Garneau JC, Bakst RL, Miles BA. Hypopharyngeal cancer: A state of the art review. Oral Oncol 2018;86:244–50.
Aupérin A. Epidemiology of head and neck cancers: an update. Curr Opin Oncol 2020;32(3):178–86.
Bradley PJ. Epidemiology of hypopharyngeal cancer. Adv Otorhinolaryngol 2019;83:1–14.
Larizadeh MH, Damghani MA, Shabani M. Epidemiological characteristics of head and neck cancers in southeast of Iran. Iran J Cancer Prev 2014;7(2):80–6.
Eckel HE, Bradley PJ. Treatment options for hypopharyngeal cancer. Adv Otorhinolaryngol 2019;83:47–53.
Habib A. Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments. J Laryngol Otol 2018;132(5):385–400.
Chung EJ, Jeong WJ, Jung YH, Kim SH, Kwon SK, Kwon TK, et al. Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo) radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: multicenter review of 266 cases. Oral Oncol 2019;89:84–94.
Larizadeh MH. Cetuximab for squamous cell carcinoma of the head and neck. Int J Cancer Manag 2017;10(11):e10502.
Larizadeh MH, Mohammadi F, Shabani M, Damghani MA. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy in laryngeal cancer. Asian Pac J Cancer Prev 2021;22(5):1633–7.
Mirzaei M, Hosseini SA, Ghoncheh M, Soheilipour F, Soltani S, Soheilipour F, et al. Epidemiology and trend of head and neck cancers in Iran. Glob Health Sci Pract 2016;8(1):189–93.
Mozaffari HR, aIzadi B, Sadeghi M, Rezaei F, Sharif Ri, Jalilian F. Prevalence of oral and pharyngeal cancers in Kermanshah province, Iran: A ten-year period. Int J Cancer Res 2016;12(3):169–75.
Rad M, Chamani G, Zarei MR, Hashemipour M. Epidemiological aspects of head and neck cancers in a group of Iranian population. Shiraz Univ Dent J 2010;10:50–6.
Hsu WL, Yu KJ, Chiang CJ, Chen TC, Wang CP. Head and neck cancer incidence trends in Taiwan, 1980-2014. Int J Head Neck Sci 2017;1(3):180–9.
Wahlberg PC, Andersson KH, Biörklund AT, Möller TR. Carcinoma of the hypopharynx: analysis of incidence and survival in Sweden over a 30‐year period. Head Neck 1998;20(8):714–9.
Braakhuis BJ, Leemans CR, Visser O. Incidence and survival trends of head and neck squamous cell carcinoma in the Netherlands between 1989 and 2011. Oral Oncol 2014;50(7):670–5.
Eckel HE, Bradley PJ. Natural history of treated and untreated hypopharyngeal cancer. Adv Otorhinolaryngol 2019;83:27–34.
Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978–2007: focus on human papillomavirus associated sites. Inter J Cancer 2011;129(3):733–41.
Takes RP, Strojan P, Silver CE, Bradly PJ, Haigentz M, Wolf GT, et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck 2012;34(2):270–81.
Visini M, Giger R, Shelan M, Elicin O, Anschuetz L. Predicting factors for oncological and functional outcome in hypopharyngeal cancer. Laryngoscope 2021;131(5):1543–9.
Kazemian A, Ghalehtaki R, Razmkhah M, Taheriyoun M, Mohammadi N, Narimani Kali M, et al. Definitive Radiotherapy with or without Concomitant or Induction Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Single Center Study in Iran. Middle East J Cancer 2020;13(2):308–15.
Hung SK, Chen HL, Hsieh CH, Hsu WL, Chang KH, Liu DW, et al. Treatment of advanced hypopharyngeal cancer-comparison of two modalities. Tzu Chi Med J 2006;18:15–21.
Huang WY, Jen YM, Chen CM, Su YF, Lin CH, Lin YS, et al. Intensity modulated radiotherapy with
concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer. Radiat Oncol 2010;5(1):1–8.
Mochiki M, Sugasawa M, Nibu KI, Asai M, Nakao K, Asakaga T. Prognostic factors for hypopharyngeal cancer: a univariate and multivariate study of 142 cases. Acta Otolaryngol Suppl 2007;559:136–44.